MS

Tara M. DeSilva from the Department of Neurosciences, Cleveland Clinic, looks at the future of therapeutic strategies for MS, focusing on targeting the central nervous system.

CEO of MS Australia Rohan Greenland highlights the breakthroughs in treating attacks on the brain and spinal cord in multiple sclerosis (MS). But his sights are set firmly on the great unmet needs: to repair damaged nerves, reverse disability, and ultimately, prevent MS.

Reducing clinical relapses and improving quality of life is at the heart of MS treatment; here Tara M. DeSilva explores the benefits of remyelinating versus neuroprotective therapies for tackling MS.